Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PegInterferon · 1 trial · 2 indications
Viral kinetic assessment using SVR 12 to either "lead-in" 4 weeks with PegInterferon + Ribavirin or no lead-in, followed by response guided therapy of 24 or 48 weeks based on viral response to treatment. Standard of care treatment stopping rules will be followed with assessment of viral response at week 12 of treatment.
| Arm | Type | Description |
|---|---|---|
| Lead-In | ACTIVE_COMPARATOR | Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin |
| No Lead-in | ACTIVE_COMPARATOR | Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin |
| Name | Type | Description |
|---|---|---|
| PegInterferon | DRUG | - |
| Ribavirin | DRUG | - |
| Telaprevir | DRUG | - |
Inclusion Criteria: 1. Hemophilia A or B 2. HCV RNA positive (PCR or branched-chain DNA Methods), Genotype 1 (a/b, mixed and unknown subtype) 3. Chronic HCV infection evidenced by HCV serology, HCV RNA or liver enzyme abnormalities present at least 6 months prior to enrollment 4. Liver biopsy or no...
PegInterferon is being investigated for the treatment of chronic hepatitis C. It is being studied in patients who also have hemophilia, as part of a clinical trial examining viral kinetics in HCV clearance. The drug is currently in Phase 1 clinical development.
Vertex Pharmaceuticals Incorporated (VRTX) is developing PegInterferon. The company is conducting clinical research on the drug for chronic hepatitis C, with a Phase 1 trial that has been completed.
PegInterferon is in Phase 1 clinical development. A Phase 1 trial studying the drug in chronic hepatitis C and hemophilia has been completed. The drug is investigational and has not been approved for any use.
PegInterferon has one completed clinical trial, NCT01704521, titled "Viral Kinetics in HCV Clearance in Subjects With Hemophilia." The study enrolled 5 participants with chronic hepatitis C and hemophilia in the United States and was actively controlled.
PegInterferon is the name used for this investigational drug in clinical development. No alternative names have been established for the drug in the available clinical trial information.